MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Siemens (NYSE: SI)
Organization & Developments: Siemens
Organization: Siemens
Siemens: Business Areas
Detection & Diagnosis
Molecular Imaging
Personalized & Precision Medicine
Surgery & Surgical Technology
Transplantation
Parents
Surgery & Surgical Technology
Children
* Immunomodulators for transplantation
* Somatus' vertically integrated clinical services and technology delay or prevent disease progression, improve quality and care coordination, and increase the use of home dialysis modalities and rates of kidney transplantation.
*Air mobility company providing air transportation and logistics for hospitals and is a transporter of human organs for transplant, Organization & Developments: Blade Air Mobility
*Architects: Amputation, Amputees, Transplantation, Implants & Prosthestics
*Architects: Biotechnology _ Genomics, Genetic Testing, Gene & DNA Sequencing, NGS (Next Generation Sequencing) Companies
*Architects: Cancer & Oncology Companies _Pharmaceuticals & Biotechnology _ Leukemia, Hematologic, Blood
*Architects: Cardiovascular, Cardiac & Cardiology Companies _ Heart Valves, Ventricular Assist (LVAD,pVAD), Artificial Heart
*Architects: Operating Room, Surgical Technology & Instruments_Transplantation
*Architects: Ophthalmology, Optometry & Ocular Health (Health IT, Devices & Technology)
*Architects: Surgical Technology _ Cardiovascular, Cardiac & Cardiology Companies
*Architects: Tissue Engineering _ CardioVascular & Blood Vessels)
*Architects: Tissue Engineering: Neurology_TBI
*Artivion, Inc. is a distributor of cryogenically preserved human tissues for cardiac and vascular transplant applications and develops medical devices.
*Biotechnology company focused on hematopoietic cell transplant therapies
*Bluebird Bio’s Approach Represents a True Paradigm Shift in the Treatment of Severe Genetic Diseases by Eliminating the Potential Complications Associated with Donor Cell Transplantation and Presenting a One-time Transformative Therapy.
*CareDx, Inc., a precision medicine company, discovers, develops, and commercializes healthcare solutions for transplant patients and caregivers worldwide
*Cell therapies completely upend the economics and supply-demand calculus of organ transplantation by using the patient’s own lymph nodes as bioreactors to grow functioning ectopic organs
*Cell therapy technology designed to facilitate organ regeneration and transplant.
*Clinical trial data for Organ Care System (OCS) has shown double to triple utilization rates for donor organs and improved outcomes (50% or more reduction in post-transplant complications).
*Company Uses a Human Cell-based Technique to Develop Synthetic Blood Vessels that Can Be Transplanted in Patients with Diseases,
*Conferences and Meetings: Advanced & Emerging Technology
*Conferences and Meetings: Advanced & Emerging Technology_Legacy/Archive 2024 and Earlier
*Developing Next-Generation Organ and Tissue Transplant Solutions
*Driving Forces: Amputation, Amputees, Transplantation, Implantables & Prosthestics
*Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people undergoing organ or cellular transplantation, and for people with autoimmune and neurodegenerative disease.
*First-in-class human organ grafts for clinical transplantation
*Focused on liver regeneration for patients with end-stage liver disease which uses lymph nodes as bioreactors and outpatient endoscopic ultrasound for transplantation of donor cells
*Focuses on heart transplantation
*Funding: Biotechnology_Genome, Genomics, Genetics, Gene Editing & Therapy, MultiOmics, Personalized & Precision Medicine
*Funding: Biotechnology_Regenerative Medicine, Stem Cell & Tissue Engineering
*Funding: Biotechnology, Biology, Biospecimens, BioChemistry
*Funding: DOD_DHA,USAMRDC_CDMRP (Congressionally Directed Medical Research Program)
*Funding: HHS_HRSA
*Funding: NIH_NHLBI
*Funding: Rehabilitation, Amputation, Transplantation, Paralysis, Prosthetics, IDD (Intellectual or Developmental Disability), LTSS (Long Term Service and Support Disability), Mobility, Exoskeletons & Assistive Technology
*Funding: Rehabilitation, Amputation, Transplantation, Paralysis, Prosthetics, IDD, Disability & Assistive Technology (Archives 2014-2017)
*Funding: Rehabilitation, Amputation, Transplantation, Paralysis, Prosthetics, IDD, Disability & Assistive Technology (Archives 2018-2019)
*Funding: Rehabilitation, Amputation, Transplantation, Paralysis, Prosthetics, IDD, Disability & Assistive Technology (Archives 2020-2022)
*Funding: Rehabilitation, Physical Therapy, Occupational Therapy (PT/OT) & Occupational Health
*Funding: Transplant
*Genome editing-based therapy designed for genetic disorders, oncology, and organ transplants.
*Hemodialysis, peritoneal dialysis, education tools and transplant support services, in-center, at home, or in a hospital, Fresenius Medical:#26, Medical Devices, $2.9B (2009)
*Jasper has developed programs, such as JSP191, an anti-CD117 monoclonal antibody, which is in clinical development as a conditioning agent that clears hematopoietic stem cells from bone marrow in patients undergoing a hematopoietic cell transplantation
*Majority of the revenue generated from its Medical segment which predominantly consists of transportation of human organs for transplant and the medical teams supporting these services.
*Manages acute pain, and transplant surgery
*Pioneers: Amputation, Amputees, Transplantation, Implants & Prosthestics
*Pioneers: Diabetes
*Pioneers: Medical Robotics
*Pioneers: Ophthalmology, Ocular Health, Optometry
*Pioneers: Pulmonology, Respiratory Care, Lungs
*Potential breakthrough in the field of organ transplantation
*Prograf, an immunosuppressant for organ transplantation.
*The alliance also extends to products for augmenting hematopoietic stem cell transplantation in cancer patients.
*The Company offers products, services, and condition-specific clinical management programs for gastrointestinal abnormalities, infectious diseases, cancer, organ and blood cell transplants, bleeding disorders, and heart failures.
*TRACT Therapeutics developing TregCel, a therapeutic platform that leverages the patient’s own regulatory T cells to treat solid organ transplant recipients and autoimmune disorders.
□ Limb reconstruction, regeneration or transplantation.
2006: $8.2 m National Institutes of Diabetes Islets/Beta Cell Transplant Registry (2006)
2011: $41M for Restoration Robotics’ Hair Transplant Robot (2011)
2012: Regrown Bones, Transplanted Faces: This Chemist Is Remaking Military Medicine (2012)
2012: Thermo Fisher Buying Transplant Dx Firm One Lambda for $925M (2012)
2014: International Society for Heart & Lung Transplantation Seeks Applications for Pulmonary Hypertension Research Grant=$100,000 - DEADLINE: JUNE 2, 2014
2014: RFA-AI-14-016: NIAID Division of Allergy, Immunology and Transplantation: Statistical and Clinical Coordinating Center (UM2)=$115,000,000 - Letter of Intent: June 18, 2014
2017: Fiscal Year 2017 (FY17) Reconstructive Transplant Research Program (RTRP) , CDMRP, US DoD
2017: NHLBI_Q--Bone Marrow Transplant Program Support
2018: HRSA_The Organ Procurement and Transplantation Network
2019: CDMRP_Reconstructive Transplant Research Program (RTRP) Request for Information (RFI), Reconstructive Transplant Research Program
2019: NIAID Division of Allergy, Immunology & Transplantation:
2020: $100M for Talaris Gives Surgeon a Shot to Reinvent Organ Transplants_xconomy
2020: American Society of Transplant Surgeons Invites Applications for Collaborative Research
2020: HRSA_Scientific Registry of Transplant Recipients - The purpose of this acquisition is to obtain services to operate the Scientific Registry of Transplant Recipients (SRTR).
2020: Mitochondrial Transplantation to Treat Ischemia-Reperfusion Injury: Interview with Dr. Alexander Schueller, CEO of cellvie
2021: AlloVir: Targeting Infectious Diseases In Stem Cell Transplant Patients
2021: American Society of Transplantation Invites Applications for Fellowship Research Grants
2021: Immunosuppression-free transplantation through placental mimicry_RePORT 〉 RePORTER
2021: NASEM_Exploring the State of the Science of Solid Organ Transplantation and Disability: Proceedings of a Workshop
2021: NHLBI_RFI_Addressing the Shortage of Donor Hearts and Lungs for Transplantation Using Donation Following Circulatory Declaration of Death (DCDD)
2021: NIAID_Emerging Science and Technology in Transplantation (U01 Clinical Trial Not Allowed)
2021: NIAID_Emerging Science and Technology in Transplantation (U01 Clinical Trial Not Allowed)
2021: NIDDK_Continuation of The Collaborative Islet Transplantation Registry (U01 Clinical Trial Not Allowed)
2021: Sanofi To Acquire Kadmon To Further Strengthen Growth of Transplant Business
2021: TransMedics: Organ Transplant Preservation Technology With Upcoming Catalysts
2022: CareDx: Organ Transplant Business Falters In Q3_ seekingalpha.com
2022: CDMRP_Reconstructive Transplant Research Program (RTRP) Anticipated Funding Opportunities for Fiscal Year 2022 (FY22)
2022: Completed a toxicology study that indicated that its immunotherapeutic technology drug, ADI-100, is safe to treat rejection of transplanted organs, skin allografting, autoimmune diseases and allergies.
2022: HRSA_Organ Procurement and Transplantation Network (OPTN) RFI _SAM.gov
2022: HRSA_Organ Procurement and Transplantation Network (OPTN) RFI_SAM.gov
2022: HRSA_Organ Procurement and Transplantation Network (OPTN) RFI_SAM.gov
2022: Nanotherapy for Immunosuppression May Lead to Diabetes Treatment
2022: NASEM_Realizing the Promise of Equity in the Organ Transplantation System_The National Academies Press
2022: Natera’s Prospera is a transplant rejection assessment blood test that can evaluate the rejection of a transplanted kidney.
2022: NCI_Limited Competition: A Data Resource for Blood and Marrow Transplants and Adoptive Cellular Therapy Research (U24 Clinical Trial Not Allowed)
2022: NIAID_NOIP_Transplantation Statistical and Clinical Coordinating Center (T-SCCC) U01 Clinical Trial Not Allowed
2022: NIAID_Transplantation Statistical and Clinical Coordinating Center (T-SCCC) (U01 Clinical Trial Not Allowed)
2022: NIDDK_Limited Competition for the Continuation of the APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO) Clinical Centers (Collaborative U01
2022: NIDDK_Limited Competition for the Continuation of the APOL1 Long-term Kidney Transplantation Outcomes Network Scientific and Data Research Center (APOLLO SDRC) (Collaborative U01
2022: Revivicor's genetically modified pig heart is first successfully transplanted in human patient
2022: U.S. surpasses 1 million organ transplants as need continues to soar
2023: American Society of Transplant Surgeons invites applications for faculty development
2023: CDMRP_FY22 Reconstructive Transplant Research Program, Congressionally Directed Medical Research Programs (CDMRP)
2023: How New Advances in Organ Transplants Are Saving Lives
2023: NHLBI_NOIP_The Blood and Marrow Transplant Clinical Trials Network
2023: NHLBI_NOIP_The Blood and Marrow Transplant Clinical Trials Network - Data CoordinatingCenter (U24)
2023: NHLBI_The Blood and Marrow Transplant Clinical Trials Network
2023: NHLBI_The Blood and Marrow Transplant Clinical Trials Network - Data Coordinating Center (U24 Clinical Trial Not Allowed)
2024: An Alabama woman is doing well after the latest experimental pig kidney transplant
2024: ARPA_H_ THEA Transplantation of Human Eye Allografts
2024: Blavatnik Family Foundation awards $5 million to Mount Sinai Health System’s Recanati/Miller Transplantation Institute
2024: CareDx Announces Transplant Community Secures Win Reaffirming Longstanding Medicare Coverage for AlloSure and AlloMap Testing
2024: CareDx Resolves Key Issues: Poised For Growth In Transplant Diagnostics
2024: CareDx, Dovetail Genomics partner for organ transplant matching
2024: CDMRP_Reconstructive Transplant Research Program (RTRP)
2024: CMS_Biden-Harris Administration Finalizes New Model to Improve Access to Kidney Transplants
2024: First Genetically Engineered Pig Kidney Transplanted into Living Patient
2024: HRSA Announces Historic Steps to Overhaul the Nation’s Organ Transplant System
2024: HRSA_American Institutes for Research (AIR) awarded $50 million Indefinite Delivery Indefinite Quantity (IDIQ) to support the Organ Procurement and Transplantation Network (OPTN).
2024: HRSA_American Institutes for Research in the Behavioral Sciences earns $50M HHS HRSA Organ Procurement and Transplantation Network (OPTN) Services IDIQ
2024: In First, Type 1 Diabetic “Cured” by Allogeneic Stem Cell Transplant
2024: In Historic Step, HRSA Makes First Ever Multi-Vendor Awards to Modernize the Nation’s Organ Transplant System and End the Current Contract Monopoly
2024: Increasing Organ Transplant Access (IOTA) Model
2024: NIAID_Human Leukocyte Antigen (HLA) and Killer-cell Immunoglobulin-like Receptor (KIR) Region Genomics in Immune-Mediated Diseases (U01 Clinical Trial Not Allowed)
2024: NIAID/NHLBI_NOSI: Somatic Cell Gene Editing Therapies To Improve Transplantation Outcomes
2024: The Paradigm Shift That Caused IBD 50 Stock TransMedics To Double This Year
2024: TransMedics Group: Huge Opportunity In Organ Transplants
2024: TransMedics' SWOT analysis: organ transplant innovator's stock faces growth hurdles
2024: TransMedics' Technology Poised To Transform Underpenetrated $8B Organ Transplant Market, Analyst Expects 22% Upside
2024: United Therapeutics Announces World’s First Successful Xenothymokidney Transplant
2024: United Therapeutics Expands Into Organ Transplants, But Tyvaso's Legal Battles Loom_ seekingalpha.com
2024: World's first combined whole eye, face transplant at NYU called success
2024:Alabama Woman Receives Nation’s Third Pig Kidney Transplant_ www.nytimes.com
2025: 10 clinical trials to watch in the first half of 2025
2025: CareDx Resolves Key Issues: Poised For Growth In Transplant Diagnostics
2025: Eledon Pharmaceuticals: At The Forefront Of The Organ Transplant Management Business
2025: Future of open-heart surgery may be through the belly
2025: NIAID_NOSI_Somatic Cell Gene Editing Therapies To Improve Transplantation Outcomes
2025: NIAID_NOSI_Somatic Cell Gene Editing Therapies To Improve Transplantation Outcomes
2025: Organ Transplant System ‘in Chaos’ as Waiting Lists Are Ignored_ www.nytimes.com
2025: Orthopaedic Research and Education Foundation invites applications for biologics research
2025: Study: LIVERguard System Reduces Post-Transplant Complications
2025: TransMedics' Turnaround: The Organ Transplant Leader Is Still A Buy
2026: NIAID_NOSI: Development of Organotypic Culture Models for Transplantation Immunology Research
2026: NIAID_Notice of Special Interest (NOSI): Development of Organotypic Culture Models for Transplantation Immunology Research
2027: NHLBI_NOSI: Pulmonary Complications of Hematopoietic Stem Cell Transplantation (HCT)
2027: NIAID/NIDDK_NOSI: Somatic Cell Gene Editing Therapies to Improve Transplantation Outcomes
3D Printing
4D Printing is a step up of 3D printing, allowing transplantation of stem cells in novel biotherapeutics such as Parkinson's Disease, and control over the shape of material even after implantation. We also aim to combat the opioid epidemic with our novel analgesic formulation implant
a) Determine the skeletal marrow and non skeletal sites of engraftment in recipient mice after transplant with donor HSCs
Ability to produce/modify transplantable cells outside the body (ex vivo).
Advances the accessibility and clinical success of transplantation,
Advocate for Equity in Healthcare and Solid Organ Transplant Systems (2024)
Also participating were Menlo Park-based Sofinnova Ventures inc., Chicago-based ARCH Venture PartnersbizWatch ARCH Venture Partners Latest from The Business Journals Sorbent raises M for heart failure drugBay Area transplant Sorbent Therapeutics raises MBa
Amplimmune is a product driven company that is developing immune-based biologics to treat patients in the areas of cancer, autoimmunity, transplantation and infectious diseases.
Architects: Biomaterials, Tissue Engineering, 3D Bioprinting & Regenerative Medicine
Autograft extracting device for autologous osteochondral transplantation |
Autoimmune Disease
b) Conduct studies to assess and quantitate the short-term and long-term bone formation achieved in mice following transplantati
Bartley Griffith Director, Cardiac and Lung Transplant Programs, University of Maryland Medical Center (2023)
Bastiano Sanna, CEO. Sanna, formerly the COO, Magenta Therapeutics and global head of stem cell transplant programs at Novartis (2019)
Bio-Engineered Corneal Transplantation (BEC)
BioPrinting
Blood Cancer
BMI OrganBank
c) Conduct studies to determine the effect of recipient age on engraftment and the bone formation response in mice transplanted
Call for Public ReviewImpact of Pre-Transplant Red Blood Cell Transfusions in Renal Allograft Rejection(2011)
Calvin Roberts, M.D., THEA Transplantation of Human Eye Allografts , ARPA-H (2024)
CareDx, Inc. (NASDAQ: CDNA)*
CDMRP_Reconstructive Transplant Research Program (RTRP)
Cell culture startup’s scaffold used in 2nd-ever synthetic trachea transplant (2011)
Cellular Transplantation
Clinical-stage specialty pharmaceutical company focused on IgA nephritis, and conditioning prior to hematopoietic stem cell transplantation
co-founded by Luis Angel, director of interventional pulmonary and lung transplantation at the [CompanyWatch allows you to recei
Construction of Spinal Cord Transplant Material-University of Pennsylvania
Corneal Transplantation :University of California, Irvine
Dan S. Kaufman, M.D., Ph.D., Associate Professor, Medicine, Division of Hematology, Oncology, and Transplantation
demonstrate that human corneal endothelial cells transplanted in vitro can be grown to densities that are comparable to in vivo
Developer of encapsulated cellular transplants for the treatment of diabetes and other serious diseases
Developing MultiStem®, a patented, adult-derived "off-the-shelf" stem cell product platform for multiple disease indications, including damage caused by myocardial infarction, bone marrow transplantation and oncology treatment support, ischemic stroke, and
DR Lynt Johnson, MD, Transplant & Hepatobiliary Surgery division, GUH
Dr Robert Kormos, MD - Director, Thoracic Transplantation & Artificial Heart Program, UPMC
Dr Thomas Fishbein, MD, Director of Intestinal and Pediatric Liver Transplantation, GUH
Dr Vinod Rustgi, MD, Director of Liver Transplantation, Georgetown University
Dr. Dipanjan Banerjee, MD, MS, Stanford University School of Medicine, Advanced Heart Failure & Cardiac Transplantation (2013)
Dr. Paulo Fontes, LyGenesis's Chief Medical Officer and former Director of the Liver Transplant Program, Starzl Transplant Institute at the University of Pittsburgh Medical Center (2022)
Dramatic enhancement of transplant organ viability and storage time-Harvard University Office of Technology Development
Drugs developed by Conatus could be useful in chronic viral hepatitis, liver transplant failure, and liver disease related to ob
eGenesis
eGenesis is a gene editing company founded by Dr. George Church at Harvard Medical School, developing xenographic organs for transplantation in humans.
Employs biological therapies (including stem cells & growth factors), tissue/biomaterials engineering, & advanced transplantatio
Endothelial cell loss in the transplanted cornea is the principal factor contributing to graft failure
Engineered RNA Binding Proteins to Deliver mRNA for Gene Therapy and Cell Transplantation-Emory University
Enlivex Therapeutics Ltd. (NASDAQ:ENLV)*
Face Transplants
FDA _ Regenerative Medicine Advanced Therapy (RMAT)
Fred Hutchinson Cancer Research Center
Gilead Sciences, Inc. (NASDAQ: GILD)*
Hand Transplants
High precision cell therapies manufactured by Orca Bio have the potential to replace conventional bone marrow transplants and expand the eligible patient population
Idogen develops tolerogenic cell therapies to prevent the patient’s immune system from attacking biological agents, transplanted organs or the body’s own cells or tissues.The term “tolerogenic” refers to the immune system’s selective tolerance of a specific pathogenic or immune activating antigen following treatment with Idogen’s therapy.
Immune Dysfunction Resulting in Allergy, Asthma, Autoimmunity, Immunodeficiency, or Transplant Rejection
Immunomonitoring of Intestinal Transplants
Including the `wet` form of macular degeneration, proliferative diabetic retinopathy, corneal transplant rejection, and neovascu
Innovative Approach to Repairing Cartilage Lesions of the Ankle and Knee Using Transplanted Tissue.
International Society for Heart & Lung Transplantation
Is working on a drug that fights organ rejection in transplant patients.
It offers the surgeon motion scaling and tremor elimination and aims to facilitate existing procedures as well as enable new ones in the domain of microsurgery, from post-oncological and trauma reconstructions to ophthalmology, organ transplantation and pediatric surgery.
Jazmin Evans Kidney Transplant Survivor
Kidney Disease
Leader in the research and development of a bioartificial pancreas, a minimally invasive cellular transplant for the treatment of insulin-dependent diabetes mellitus ("IDDM")
liver transplantation
LVADs are used to bridge patients until a donor heart becomes available (Bridge-to-Transplant therapy) or, increasingly, as a long-term alternative to transplantation (Destination Therapy.)
Maj David Leeser – Transplant Surgery consultant (WRAMC)
MedImmune is a biotechnology company formed to market products for infectious diseases and transplantation medicine.
Minimally invasive, encapsulated cellular transplant device for the treatment of diabetes. The company sold its assets to Novoce
Miromatrix Medical is developing a way to grow transplant organs in labs.
Monitoring of kidney transplant and dialysis patients
most evident in microvascular tissue transplantation and digit reattachment in children
Multiple Myeloma
Murine model of stem cell transplantation
Musculoskeletal Transplant Foundation
Novus Therapeutics, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people requiring an organ or cell-based transplant, and for pe
One Lambda
One Lambda makes test kits, laboratory instruments and computer software primarily used in transplant medicine.
only current treatment for corneal opacification is full corneal transplantation.
Organ Transplants
Pancreatic islet isolation and transplantation specialists
Patients with abnormal renal function, and especially patients receiving dialysis or transplantation, are at greatly increased r
Pediatric liver transplantation and extracorporeal membrane oxygenation
Pediatric transplant unit, Georgetown
Products targeted on rare inherited disorders, kidney disease, orthopaedics, transplant and immune disease, cancer, and diagnost
Project Goal: To develop and optimize standardized manufacturing systems for a novel type of pharmaceutical-grade gene transfer vehicle for vaccination, gene therapy and tissue transplantation applications.
Promotion of Corneal Transplant Longevity Using Targeted Delivery of Anti-Apoptotic Genes - Schepens
Protocol for Composite Facial Allograft Transplantation
Public review of The Impact of Pre-Transplant Red Blood Cell Transfusions in Renal Allograft Rejection February 3, 2011.
Regenerative Medicine
Reset a patient’s immune system via stem cell transplant to cure autoimmune diseases, blood cancers and genetic diseases
Restoration Robotics (HAIR)
Revivicor is an early-stage biotechnology company developing engineered tissues and whole organs for human transplantation.
Seres Therapeutics, Inc. (Nasdaq: MCRB)*
Siemionow earned lots of renown in 2008, after leading a team of Clinic surgeons who performed the nation’s first near total face transplant.
Solomon Moshkevich, Natera, Inc. - General Manager of Oncology & Transplant (2021)
Stem Cells
Strive’s model combines advanced technology with high-touch patient care to slow kidney disease progression, prevent unnecessary and costly hospitalizations, and expand access to optimal renal replacement therapies such as home dialysis and transplants.
Such as the liver, spleen and kidney involved in trauma, cancer and transplantation even in the presence of coagulation failure
Sunil Shroff, MS. FRCS, D Urol, President, TN, Telemedicine Society of India, Senior Consultant Urologist & Transplant Surgeon, Madras Medical Mission, India (2021)
Systemic gene therapy for massive skeletal tissue damage by means of hematopoietic stem cell (HSC) transplant
The Company focuses on immunomodulatory enzymes for treatment and prevention of rare diseases, as well as provides transplant rejection.
The company is developing a computer-guided system that helps harvest healthy hair follicles for transplantation.
The company, based in Washington Square, was co-founded by Dr. Chad Gordon the surgeon who completed the first successful face transplant.
The National Institute of Allergy and Infectious Diseases (NIAID) is interested in supporting research that applies somatic cell gene editing (SCGE) approaches in animal models or human tissues or organs excluded from clinical use to improve graft survival and outcomes for recipients of allogenic or xenogeneic solid organ or pancreatic islet transplants, or vascularized composite allografts (VCA).
The purpose of this Notice of Funding Opportunity (NOFO) is to support research that improves understanding of basic mechanisms and biomarkers of trained immunity (i.e., innate immune memory), plus the functional implications of trained immunity, related to 1) immune system development and function, 2) immunity to vaccines or natural infections, or 3) allergic diseases, autoimmunity, or rejection of organ/tissue/cell transplantation.
The technology also will help lengthen the period of time that tissues, cells and organs for transplantation can exist outside t
This approach circumvents the need for a bone marrow transplant since it leverages blood stem cells intrinsic capacity to self-renew in a patient's bone marrow and produce new blood cells of all types
This RFI is to solicit public comments on existing immunology resources, the future needs of the research community, and potential future direction(s) of data and knowledge management that will enable the Division of Allergy, Immunology and Transplantation (DAIT), National Institute of Allergy and infectious Diseases (NIAID), to determine the need for a knowledgebase for immunology research and, if so, its scope and functionalities.
Tissue and Limb Transplantation Medical Development
Tissue Transplant and Regeneration Device and Method to Treat Ischemic Heart Disease (BIDMC 960)-Beth Israel Deaconess Medical Center
To fabricate an entire organ or a large piece of tissue for transplantation, a predesigned scaffold with the patient-specific an
Tolera’s drug is designed to suppress the immune systems of patients who have received organ transplants, which can fail because the body rejects and attacks the transplanted organ.
Transfusion & Transplantation Technologies ("3Ti") - www.3tibio.com
TransMedics Group, Inc. (NASDAQ: TMDX)*
Transplant
Transplant centers use the kits to determine the compatibility of donors and recipients to reduce the potential for organ rejection
Transplant Immunology
Transplantation
Transplantation of engineered cells is an emerging therapy for a wide variety of diseases
Transplantation, Tolerance, and Tumor Immunology Study Section
world leader in diagnostics, the leading supplier of medicines for cancer and transplantation and a market leader in virology
Wounded Warrior Candidate Technology & SMEs
XDx is a molecular diagnostics company focused on the discovery, development and commercialization of non-invasive tests for the monitoring of transplant rejection and autoimmune diseases
Xenotransplantation